[Advances of study on PPARgamma/PPARgamma ligand in hematologic malignancies].
Recently, along with the thorough investigation on the gene and molecular biology of peroxisome proliferators activated receptorgamma (PPARgamma), the therapeutic effects of PPARgamma ligand and its potential mechanism were gradually recognized. PPARgamma will probably become a new target of oncotherapy and is now extensively followed by researchers. This review focuses the advances of study on PPARgamma distribution in tissue, its function, its ligand in relationship with hematologic malignancies including acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, lymphoma, multiple myeloma and so on.
Huang
Hai-Wen
HW
Department of Hematology, The First Hospital, Suzhou University, Jiangsu Institute of Hematology, Suzhou 215006, Jiangsu Province, China.
Wu
De-Pei
DP
D019337:Hematologic Neoplasms / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008024:Ligands; D047495:PPAR gamma / Q000378:metabolism*
D008024:Ligands; D047495:PPAR gamma